Gilead Sciences (GILD) 113.45 $GILD
What to Make of Gilead Sciences Inc.'s Third-Quarter Earnings Miss
Keith Speights, The Motley Fool - Motley Fool - 30 mins ago
Gilead Sciences reported its third-quarter financial results after the market closed on Tuesday, and a quick glance at the stock's price would certainly lead you to think those results weren't good, as shares fell more than 3% immediately after the...
GILD: 113.45 (+0.86)
Gilead beats Street 3Q forecasts
AP - 22 mins ago
FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Tuesday reported third-quarter profit of $2.73 billion.
GILD: 113.45 (+0.86)
Civitas Buyout Shores Up Acorda's Wall Street Cred
at Investor's Business Daily - 52 mins ago
It's been an interesting year for drugmaker Acorda Therapeutics. The neurology specialist has been working to diversify from Ampyra, a drug that helps multiple sclerosis patients walk and which provided 90% of Acorda's (ACOR) revenue in the most...
GILD: 113.45 (+0.86), ACOR: 35.06 (+0.60)
Final Glance: Biotechnology companies
AP - 1 hr 4 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
S&P 500 Moves Higher for October as Investors Await Federal Reserve Outlook
at The Street - 2 hrs 15 mins ago
The S&P 500 Index, fueled by third-quarter corporate earnings and better-than-feared economic data from China and Europe, is now higher for the month of October.
MSG: 72.99 (+7.21), GILD: 113.45 (+0.86), FB: 80.77 (+0.49), PFE: 29.09 (+0.06), DD: 67.95 (+0.07), TWTR: 43.78 (-4.78)
Gilead Sciences (GILD) Stock Falls in After-Hours Trading After Earnings Miss
at The Street - 2 hrs 57 mins ago
Shares of Gilead Sciences (GILD) dropped in after-hours trading Tuesday after the biotech company reported third-quarter earnings that came up short of analysts' expectations.
GILD: 113.45 (+0.86)
Gilead Sciences Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:06PM CDT
--- Sovaldi Sales of $2.80 billion -
GILD: 113.45 (+0.86)
Video: Facebook, Gilead Post Earnings After The Close
at Investor's Business Daily - Tue Oct 28, 1:00PM CDT
Two top stocks on Leaderboard's Leaders List report quarterly earnings after the close on Tuesday: Facebook and Gilead Sciences. Here's a breakdown of what analysts expect. The social network's earnings are seen jumping 60% to 40 cents a share minus...
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), FB: 80.77 (+0.49), MRK: 55.85 (-0.60)
Midday Glance: Biotechnology companies
AP - Tue Oct 28, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Video: Aetna Falls On Costs; Centene Up On Medicaid
at Investor's Business Daily - Tue Oct 28, 11:38AM CDT
Aetna (AET) beat forecasts and raised its earnings guidance for the year, but shares are down amid higher patient medical costs. The insurance provider's earnings rose 19.3% to $1.79 a share, handily topping views by 21 cents, and revenue grew 13.1%...
CNC: 88.65 (+6.43), GILD: 113.45 (+0.86), UNH: 92.64 (+0.51), AET: 77.23 (-1.95), WLP: 120.00 (-0.34)
What to Expect When Gilead (GILD) Reports Third-Quarter Earnings Today
at The Street - Tue Oct 28, 10:55AM CDT
Shares of Gilead Sciences (GILD) were up Tuesday ahead of the company's scheduled third-quarter earnings report after the market close. Here's what analysts are expecting from the biotech giant.
GILD: 113.45 (+0.86)
3 Ways You'll Know Gilead Sciences, Inc. Stock Is Still On Track
Keith Speights, The Motley Fool - Motley Fool - Tue Oct 28, 10:38AM CDT
Few biotechs have raced ahead in 2014 like Gilead Sciences has. The company's stock has soared around 50% so far this year. Gilead's red-hot hepatitis-C franchise is energizing investors. It received regulatory approval for its first oncology drug...
GILD: 113.45 (+0.86)
Early Glance: Biotechnology companies
AP - Tue Oct 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Cramer on Stocks and Investing: How to Game This Clueless Market
at The Street - Tue Oct 28, 9:23AM CDT
As long as you use common sense, you will be able to profit.
KMI: 39.17 (+0.24), FDX: 168.20 (+2.98), MU: 32.61 (+0.31), GILD: 113.45 (+0.86), STX: 59.47 (+0.73), CMG: 645.85 (+15.74), PG: 86.47 (+0.52), UPS: 102.90 (+0.65), REGN: 397.89 (-9.27), PEP: 95.26 (+0.64), DRI: 52.03 (+0.61)
Amgen Beats Earnings Estimates, What's Next for AMGN? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Oct 27, 11:59PM CDT
Amgen had a solid beat on earnings, and AMGN stock was rising after hours.
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales
Sean Williams, The Motley Fool - Motley Fool - Mon Oct 27, 4:16PM CDT
Big pharma giant Merck hasn't been shy about the fact that it's in the midst of a multi-year turnaround strategy focused on generating organic and acquired growth, but shareholders sometimes need a reminder that there could be bumps along the...
GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble
at Investor's Business Daily - Mon Oct 27, 2:38PM CDT
Shares of Gilead Sciences (GILD) hit a new high near 113 in the stock market today as the biotech prepared to deliver its Q3 report after the close Tuesday, while an analyst noted that a couple of its potential competitors seemed to be faltering....
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Gilead Sciences (GILD) Breaks Through Resistance at $112.59
Comtex SmarTrend(R) - Mon Oct 27, 12:25PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $109.59 today and has reached the first level of resistance at $112.59. Analysts will be watching for a cross of the next upside pivot targets of $114.46 and $119.33.
GILD: 113.45 (+0.86)
Will Marijuana-Based Pharmaceuticals Make Drugs More Affordable?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 11:21AM CDT
Drugs that have been deemed "safe and effective" by the likes of the Food and Drug Administration have a major strike against them: their often astronomical price tag. Perhaps it's a sign of the times that the newly approved cancer drugs regularly...
JNJ: 104.79 (+0.72), GWPH: 75.47 (+1.35), GILD: 113.45 (+0.86)
Stock Market News for October 27, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:10AM CDT
Benchmarks posted solid gains on Friday, banking on upbeat quarterly results from Microsoft and Procter & Gamble
JNJ: 104.79 (+0.72), AMZN: 295.59 (+5.62), GILD: 113.45 (+0.86), MRK: 55.85 (-0.60), PFE: 29.09 (+0.06), ABBV: 60.93 (+0.44), PG: 86.47 (+0.52), MSFT: 46.49 (+0.58)
What to Make of Gilead Sciences Inc.'s Third-Quarter Earnings Miss
Keith Speights, The Motley Fool - Motley Fool - 30 mins ago
Gilead Sciences reported its third-quarter financial results after the market closed on Tuesday, and a quick glance at the stock's price would certainly lead you to think those results weren't good, as shares fell more than 3% immediately after the...
GILD: 113.45 (+0.86)
Gilead beats Street 3Q forecasts
AP - 22 mins ago
FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Tuesday reported third-quarter profit of $2.73 billion.
GILD: 113.45 (+0.86)
Civitas Buyout Shores Up Acorda's Wall Street Cred
at Investor's Business Daily - 52 mins ago
It's been an interesting year for drugmaker Acorda Therapeutics. The neurology specialist has been working to diversify from Ampyra, a drug that helps multiple sclerosis patients walk and which provided 90% of Acorda's (ACOR) revenue in the most...
GILD: 113.45 (+0.86), ACOR: 35.06 (+0.60)
Final Glance: Biotechnology companies
AP - 1 hr 4 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
S&P 500 Moves Higher for October as Investors Await Federal Reserve Outlook
at The Street - 2 hrs 15 mins ago
The S&P 500 Index, fueled by third-quarter corporate earnings and better-than-feared economic data from China and Europe, is now higher for the month of October.
MSG: 72.99 (+7.21), GILD: 113.45 (+0.86), FB: 80.77 (+0.49), PFE: 29.09 (+0.06), DD: 67.95 (+0.07), TWTR: 43.78 (-4.78)
Gilead Sciences (GILD) Stock Falls in After-Hours Trading After Earnings Miss
at The Street - 2 hrs 57 mins ago
Shares of Gilead Sciences (GILD) dropped in after-hours trading Tuesday after the biotech company reported third-quarter earnings that came up short of analysts' expectations.
GILD: 113.45 (+0.86)
Gilead Sciences Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:06PM CDT
--- Sovaldi Sales of $2.80 billion -
GILD: 113.45 (+0.86)
Video: Facebook, Gilead Post Earnings After The Close
at Investor's Business Daily - Tue Oct 28, 1:00PM CDT
Two top stocks on Leaderboard's Leaders List report quarterly earnings after the close on Tuesday: Facebook and Gilead Sciences. Here's a breakdown of what analysts expect. The social network's earnings are seen jumping 60% to 40 cents a share minus...
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), FB: 80.77 (+0.49), MRK: 55.85 (-0.60)
Midday Glance: Biotechnology companies
AP - Tue Oct 28, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Video: Aetna Falls On Costs; Centene Up On Medicaid
at Investor's Business Daily - Tue Oct 28, 11:38AM CDT
Aetna (AET) beat forecasts and raised its earnings guidance for the year, but shares are down amid higher patient medical costs. The insurance provider's earnings rose 19.3% to $1.79 a share, handily topping views by 21 cents, and revenue grew 13.1%...
CNC: 88.65 (+6.43), GILD: 113.45 (+0.86), UNH: 92.64 (+0.51), AET: 77.23 (-1.95), WLP: 120.00 (-0.34)
What to Expect When Gilead (GILD) Reports Third-Quarter Earnings Today
at The Street - Tue Oct 28, 10:55AM CDT
Shares of Gilead Sciences (GILD) were up Tuesday ahead of the company's scheduled third-quarter earnings report after the market close. Here's what analysts are expecting from the biotech giant.
GILD: 113.45 (+0.86)
3 Ways You'll Know Gilead Sciences, Inc. Stock Is Still On Track
Keith Speights, The Motley Fool - Motley Fool - Tue Oct 28, 10:38AM CDT
Few biotechs have raced ahead in 2014 like Gilead Sciences has. The company's stock has soared around 50% so far this year. Gilead's red-hot hepatitis-C franchise is energizing investors. It received regulatory approval for its first oncology drug...
GILD: 113.45 (+0.86)
Early Glance: Biotechnology companies
AP - Tue Oct 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Cramer on Stocks and Investing: How to Game This Clueless Market
at The Street - Tue Oct 28, 9:23AM CDT
As long as you use common sense, you will be able to profit.
KMI: 39.17 (+0.24), FDX: 168.20 (+2.98), MU: 32.61 (+0.31), GILD: 113.45 (+0.86), STX: 59.47 (+0.73), CMG: 645.85 (+15.74), PG: 86.47 (+0.52), UPS: 102.90 (+0.65), REGN: 397.89 (-9.27), PEP: 95.26 (+0.64), DRI: 52.03 (+0.61)
Amgen Beats Earnings Estimates, What's Next for AMGN? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Oct 27, 11:59PM CDT
Amgen had a solid beat on earnings, and AMGN stock was rising after hours.
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Merck & Co., Inc. Earnings: Patent Losses and Competition Weigh on Sales
Sean Williams, The Motley Fool - Motley Fool - Mon Oct 27, 4:16PM CDT
Big pharma giant Merck hasn't been shy about the fact that it's in the midst of a multi-year turnaround strategy focused on generating organic and acquired growth, but shareholders sometimes need a reminder that there could be bumps along the...
GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble
at Investor's Business Daily - Mon Oct 27, 2:38PM CDT
Shares of Gilead Sciences (GILD) hit a new high near 113 in the stock market today as the biotech prepared to deliver its Q3 report after the close Tuesday, while an analyst noted that a couple of its potential competitors seemed to be faltering....
JNJ: 104.79 (+0.72), GILD: 113.45 (+0.86), MRK: 55.85 (-0.60)
Gilead Sciences (GILD) Breaks Through Resistance at $112.59
Comtex SmarTrend(R) - Mon Oct 27, 12:25PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $109.59 today and has reached the first level of resistance at $112.59. Analysts will be watching for a cross of the next upside pivot targets of $114.46 and $119.33.
GILD: 113.45 (+0.86)
Will Marijuana-Based Pharmaceuticals Make Drugs More Affordable?
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 11:21AM CDT
Drugs that have been deemed "safe and effective" by the likes of the Food and Drug Administration have a major strike against them: their often astronomical price tag. Perhaps it's a sign of the times that the newly approved cancer drugs regularly...
JNJ: 104.79 (+0.72), GWPH: 75.47 (+1.35), GILD: 113.45 (+0.86)
Stock Market News for October 27, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:10AM CDT
Benchmarks posted solid gains on Friday, banking on upbeat quarterly results from Microsoft and Procter & Gamble
JNJ: 104.79 (+0.72), AMZN: 295.59 (+5.62), GILD: 113.45 (+0.86), MRK: 55.85 (-0.60), PFE: 29.09 (+0.06), ABBV: 60.93 (+0.44), PG: 86.47 (+0.52), MSFT: 46.49 (+0.58)
